TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32089329

Group type: EXPERIMENTAL
Intervention: Triple fixed combination (TFC) of bimatoprost 0.01%/brimonidine 0.15%/timolol 0.5% ophthalmic solution
Number of subjects: 185

Group type: COMPARATOR
Intervention: Dual fixed combination (DFC) of brimonidine 0.2%/timolol 0.5%
Number of subjects: 185
Study: 34487415

Group type: EXPERIMENTAL
Intervention: Stent overlap
Number of subjects: 5605

Group type: COMPARATOR
Intervention: No stent overlap
Number of subjects: 5605
Study: 33407204

Group type: EXPERIMENTAL
Intervention: Perturbation-based balance training (PBT) - three 30-minute sessions in the Computer Assisted Rehabilitation Environment.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Usual care plus PBT (intervention group).
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PBT protocol acceptability (intervention group).
Number of subjects: 80
Study: 35602629

Group type: EXPERIMENTAL
Intervention: Bipolar plasma needle electrode
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bipolar plasma ring (control)
Number of subjects: 100
Study: 34512959

Group type: EXPERIMENTAL
Intervention: Niclosamide (NCS) as add-on therapy to standard of care
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard of care therapy only (Control)
Number of subjects: 150
Study: 35939620

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 302
Study: 33651849

Group type: EXPERIMENTAL
Intervention: ROLLER‐MASSAGER
Number of subjects: 14

Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 14
Study: 32370804

Group type: EXPERIMENTAL
Intervention: Prenatal counseling sessions (4 sessions)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 108
Study: 35044927

Group type: EXPERIMENTAL
Intervention: My Possible Self (MPS)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: NHSWBP (NHSH Staff Wellbeing Project)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 169
Study: 33421836

Group type: EXPERIMENTAL
Intervention: Nitrous oxide gas (N2O) administration during childbirth
Number of subjects: 2070

Group type: EXPERIMENTAL
Intervention: Morphine administration during childbirth
Number of subjects: 2070

Group type: EXPERIMENTAL
Intervention: Combination of both drugs with severe pain during labor
Number of subjects: 2070
Study: 35332571

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 192

Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 192
Study: 34051406

Group type: EXPERIMENTAL
Intervention: 9-h light and 15-h dark regime (long dark phase, LDP)
Number of subjects: 72

Group type: COMPARATOR
Intervention: 16-h light and 8-h dark (control)
Number of subjects: 72
Study: 36222186

Group type: EXPERIMENTAL
Intervention: Higher GBP2 expression
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Integrating GBP2 expression with TNM stage
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: GBP2 expression
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: GBP2
Number of subjects: 286
Study: 33010242

Group type: EXPERIMENTAL
Intervention: Tetravalent vaccine (Ad26.Mos4.HIV)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Tetravalent vaccine
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 35487130

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (AA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Occlusal splints (OS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 0
Study: 32729269

Group type: EXPERIMENTAL
Intervention: Dual-Switching Monopolar Radiofrequency Ablation (DSM-RFA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Single-Switching Monopolar Radiofrequency Ablation (SSM-RFA)
Number of subjects: 80
Study: 32154945

Group type: EXPERIMENTAL
Intervention: Low strain rate (n = 21)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: High strain rate (n = 20)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (n = 16)
Number of subjects: 102
Study: 35876246

Group type: EXPERIMENTAL
Intervention: Antenatal diet and exercise intervention
Number of subjects: 326

Group type: COMPARATOR
Intervention: Sleep duration <6 hours
Number of subjects: 326
Study: 33248457

Group type: EXPERIMENTAL
Intervention: PREVSAM model (intervention group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 0
Study: 35950573

Group type: EXPERIMENTAL
Intervention: Government performing well
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Government performing badly
Number of subjects: 357

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 357
Study: 32038101

Group type: EXPERIMENTAL
Intervention: 1% atropine
Number of subjects: 660

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 660
Study: 35665918

Group type: EXPERIMENTAL
Intervention: NRTIs included in the treatment regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: NRTIs omitted from the treatment regimen
Number of subjects: 0
Study: 34225360

Group type: EXPERIMENTAL
Intervention: Low-protein overfeeding (3% protein)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: High-protein overfeeding (30% protein)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Normal-protein overfeeding (20% protein)
Number of subjects: 77
Study: 36418659

Group type: EXPERIMENTAL
Intervention: Mozart music intervention applied immediately after surgery
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mozart music intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 50
Study: 33931178

Group type: EXPERIMENTAL
Intervention: Drugs with a central action mechanism
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Drugs with a peripheral action mechanism
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Dopamine antagonists (specific drug type not mentioned)
Number of subjects: 88
Study: 32320010

Group type: EXPERIMENTAL
Intervention: Specialty team-based services for first-episode psychosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 0
Study: 33175074

Group type: EXPERIMENTAL
Intervention: NIDCAP follow-up program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Routine care without NIDCAP
Number of subjects: 20
Study: 35219340

Group type: EXPERIMENTAL
Intervention: SPIN-SELF Program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study: 34745397

Group type: EXPERIMENTAL
Intervention: Kiatsu with Ki training
Number of subjects: 69
Study: 35854251

Group type: EXPERIMENTAL
Intervention: ImRs (Imagery Rescripting)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: PE (Prolonged Exposure)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: EMDR (Eye Movement Desensitization and Reprocessing)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Simultaneous PTSD treatment
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Sequential PTSD treatment
Number of subjects: 205
Study: 32713006

Group type: EXPERIMENTAL
Intervention: Renal-specific ONS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Macronutrient-matched ONS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard ONS
Number of subjects: 0
Study: 36127722

Group type: COMPARATOR
Intervention: Sublay Mesh‐Only Repair
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Posterior Component Separation with Transversus Abdominis Release (TAR)
Number of subjects: 56
Study: 33609066

Group type: EXPERIMENTAL
Intervention: Hypokalaemia (serum potassium <4 mmol/L)
Number of subjects: 4822

Group type: EXPERIMENTAL
Intervention: Hyperkalaemia (serum potassium >5 mmol/L)
Number of subjects: 4822

Group type: COMPARATOR
Intervention: Normokalaemia (serum potassium 4–5 mmol/L)
Number of subjects: 4822

Group type: EXPERIMENTAL
Intervention: All-cause and cardiovascular death
Number of subjects: 4822
Study: 32119749

Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN)
Number of subjects: 386
Study: 34695841

Group type: EXPERIMENTAL
Intervention: Regional nodal irradiation with IMNI
Number of subjects: 735

Group type: COMPARATOR
Intervention: Regional nodal irradiation without IMNI
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Regional nodal irradiation with IMNI (subgroup analysis for mediocentrally located tumors)
Number of subjects: 735

Group type: COMPARATOR
Intervention: Regional nodal irradiation without IMNI (subgroup analysis for mediocentrally located tumors)
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Regional nodal irradiation with IMNI (subgroup analysis for breast cancer mortality)
Number of subjects: 735

Group type: COMPARATOR
Intervention: Regional nodal irradiation without IMNI (subgroup analysis for breast cancer mortality)
Number of subjects: 735
Study: 34726661

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen therapy (ET) for 12 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (PLC) for 12 weeks
Number of subjects: 31
Study: 32450367

Group type: EXPERIMENTAL
Intervention: Intensive Behavioral Therapy (IBT) alone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intensive Behavioral Therapy (IBT) with liraglutide 3.0 mg/d
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intensive Behavioral Therapy (IBT) with liraglutide and a 12-week meal replacement diet (Multi-component)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Early weight loss
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Self-monitoring and medication adherence
Number of subjects: 150
Study: 35947347

Group type: EXPERIMENTAL
Intervention: Triptorelin pamoate PR 3-month (15 mg per injection, once every 12 weeks)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Triptorelin acetate PR 1-month (3.75 mg per injection, once every 4 weeks)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 300
Study: 34865631

Group type: EXPERIMENTAL
Intervention: Research MRI (3 Tesla Philips Ingenia®) at baseline and 6 months
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Research MRI (3 Tesla Philips Ingenia®)
Number of subjects: 86
Study: 34647442

Group type: EXPERIMENTAL
Intervention: RIC transplant
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: RIC transplant from sibling donor
Number of subjects: 932

Group type: EXPERIMENTAL
Intervention: RIC transplant from matched unrelated donor
Number of subjects: 932
Study: 33298201

Group type: EXPERIMENTAL
Intervention: Lutein 20 mg/d along with a low-calorie diet (LCD) for 10 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo along with a low-calorie diet (LCD) for 10 weeks
Number of subjects: 48
Study: 37749609

Group type: EXPERIMENTAL
Intervention: Planetary Health Plate (PHP) graphic
Number of subjects: 1178

Group type: COMPARATOR
Intervention: Control (no signage)
Number of subjects: 1178
Study: 32701542

Group type: EXPERIMENTAL
Intervention: AnaConDa‐S (reflection group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Circle system (low flow)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Circle system (minimal flow)
Number of subjects: 40
Study: 33785016

Group type: EXPERIMENTAL
Intervention: Duloxetine (30 mg/day for one week before surgery and 60 mg/day for six weeks after surgery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care-as-usual (placebo)
Number of subjects: 0
Study: 32059702

Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravascular Ultrasound (IVUS)
Number of subjects: 12
Study: 35925421

Group type: EXPERIMENTAL
Intervention: True air purifier system (TR)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham air purifier system (SR)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: True air purifier system (TR) in non-smoker rooms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: True air purifier system (TR) in smoker rooms
Number of subjects: 12
Study: 33758231

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 32693847

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis DSM 29784 (1×10^9 cfu/kg)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Enzymes (300 mg/kg)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis DSM 29784 and Enzymes (1×10^9 cfu/kg and 300 mg/kg)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Enramycin (250 mg/kg)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Basal diet (control)
Number of subjects: 1200
Study: 33729952

Group type: EXPERIMENTAL
Intervention: Boosted Randomness Algorithm
Number of subjects: 0
Study: 36074461

Group type: EXPERIMENTAL
Intervention: Intensive diabetes therapy
Number of subjects: 1441
Study: 33495597

Group type: EXPERIMENTAL
Intervention: Genetic risk score
Number of subjects: 2780

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure (DBP)
Number of subjects: 2780
Study: 34648753

Group type: EXPERIMENTAL
Intervention: Right semi-elevated side-lying position
Number of subjects: 60
Study: 34436523

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Ramipril plus Bisoprolol
Number of subjects: 174
Study: 35284698

Group type: EXPERIMENTAL
Intervention: Intravenous morphine plus ibuprofen (5 mg morphine with 800 mg ibuprofen)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Intravenous morphine plus ketorolac (5 mg morphine with 30 mg ketorolac)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Intravenous morphine alone (5 mg morphine)
Number of subjects: 195
Study: 33190659

Group type: EXPERIMENTAL
Intervention: Active rPAS
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control rPAS
Number of subjects: 32
Study: 33608841

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1,000 mg)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 32611242

Group type: EXPERIMENTAL
Intervention: Plant stanol ester-enriched spread (3.0 g plant stanols/d)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (spread without added plant stanol esters)
Number of subjects: 90
Study: 35027281

Group type: EXPERIMENTAL
Intervention: Standard of care plus the care of a pharmacist for 12 months
Number of subjects: 239

Group type: COMPARATOR
Intervention: Standard of care (control arm) for 12 months
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Phase 2 intervention with a pharmacist for 6 months (for control patients who did not achieve A1C < 8%)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Standard of care plus the care of a pharmacist
Number of subjects: 239

Group type: COMPARATOR
Intervention: Standard of care (control arm)
Number of subjects: 239
Study: 35906314

Group type: EXPERIMENTAL
Intervention: VIPP‐PRE intervention (n=39)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Dummy intervention (n=34)
Number of subjects: 73
Study: 33717089

Group type: EXPERIMENTAL
Intervention: Two-marker bio-signature
Number of subjects: 1403

Group type: EXPERIMENTAL
Intervention: Seven-marker bio-signature
Number of subjects: 1403

Group type: COMPARATOR
Intervention: C-reactive protein (CRP)
Number of subjects: 1403
Study: 35929048

Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Breathing exercises (3 times a day for 30 minutes on the first three post-operative days)
Number of subjects: 132
Study: 33128847

Group type: EXPERIMENTAL
Intervention: Generic pantoprazole sodium enteric-coated tablets
Number of subjects: 36

Group type: COMPARATOR
Intervention: Branded pantoprazole sodium enteric-coated tablets
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Generic and branded pantoprazole sodium enteric-coated tablets
Number of subjects: 36
Study: 33577235

Group type: EXPERIMENTAL
Intervention: Rehabilitative ultrasound imaging (RUSI)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pressure biofeedback unit (PBU)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (none)
Number of subjects: 40
Study: 32370731

Group type: EXPERIMENTAL
Intervention: Oral 600mg ALA twice daily for 6 months
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 36890541

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA) administration (1000 mg before skin incision and 6 hours after)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (without TXA administration)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA) administration
Number of subjects: 59
Study: 34936382

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxycycline 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cephalexin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All subjects receiving antibiotics
Number of subjects: 0
Study: 32217888

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (electro or sham)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Pharmacological hot flash treatment (gabapentin or placebo)
Number of subjects: 108
Study: 33997903

Group type: EXPERIMENTAL
Intervention: Health information exchange (HIE) event notification intervention
Number of subjects: 23
Study: 34432899

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (2.2 mg on days 1 and 2; 13.2 mg on days 3 and 4)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Voriconazole (400 mg twice on day 1, then 3 doses of 200 mg every 12 hours)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 33647066

Group type: EXPERIMENTAL
Intervention: Normal weight NHBs at baseline
Number of subjects: 70750

Group type: EXPERIMENTAL
Intervention: NHBs in general
Number of subjects: 70750

Group type: EXPERIMENTAL
Intervention: Age-stratified results for NHBs
Number of subjects: 70750

Group type: EXPERIMENTAL
Intervention: Joint influence of NHB race/ethnicity and weight status
Number of subjects: 70750

Group type: COMPARATOR
Intervention: NHBs vs NHWs
Number of subjects: 70750
Study: 33181558

Group type: EXPERIMENTAL
Intervention: Closed-loop BIS-guided propofol and remifentanil titration
Number of subjects: 204

Group type: COMPARATOR
Intervention: Manual BIS-guided propofol and remifentanil titration
Number of subjects: 204
Study: 37421161

Group type: EXPERIMENTAL
Intervention: Whole-brain WM networks derived from young adults using connectome-based predictive modeling
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Individual differences in WM performance
Number of subjects: 110
Study: 34953469

Group type: EXPERIMENTAL
Intervention: RA1 mouth rinse solution (0.8% proanthocyanidin-enriched extract from Rumex acetosa)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo mouth rinse
Number of subjects: 35
Study: 32446304

Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride gargle (15 mL of 0.15% solution)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Water mouthwash (control group)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride gargle
Number of subjects: 72
Study: 33492774

Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: R-COMP
Number of subjects: 90
Study: 36346807

Group type: EXPERIMENTAL
Intervention: Adhera® MejoraCare Digital Program
Number of subjects: 96

Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 96
Study: 33977739

Group type: EXPERIMENTAL
Intervention: ISGMS (Instantaneous Scanning Glucose Monitoring System) combined with fingertip blood glucose monitoring
Number of subjects: 110

Group type: COMPARATOR
Intervention: Fingertip blood glucose monitoring
Number of subjects: 110
Study: 34689825

Group type: EXPERIMENTAL
Intervention: Preoperative physiotherapy
Number of subjects: 432

Group type: COMPARATOR
Intervention: Control group (booklet alone)
Number of subjects: 432
Study: 33669979

Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo Dry Needling (placebo DN)
Number of subjects: 32
Study: 32053298

Group type: EXPERIMENTAL
Intervention: Plasma exchange (seven plasma exchanges within 14 days after randomization)
Number of subjects: 704

Group type: COMPARATOR
Intervention: No plasma exchange (control group)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Reduced-dose regimen of oral glucocorticoids
Number of subjects: 704

Group type: COMPARATOR
Intervention: Standard-dose regimen of oral glucocorticoids
Number of subjects: 704
Study: 36235824

Group type: EXPERIMENTAL
Intervention: Stevia-sweetened beverage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucose and maltodextrin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study: 33847473

Group type: EXPERIMENTAL
Intervention: HA+PRP
Number of subjects: 24

Group type: COMPARATOR
Intervention: HA alone
Number of subjects: 24
Study: 32773377

Group type: EXPERIMENTAL
Intervention: Messages about breast cancer risk reduction and breastfeeding
Number of subjects: 288

Group type: COMPARATOR
Intervention: Breastfeeding-only messages
Number of subjects: 288
Study: 36169954

Group type: COMPARATOR
Intervention: Standardized low-fat diet (<25% of energy intake)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Personalized diet estimating PPGR
Number of subjects: 199

Group type: COMPARATOR
Intervention: Standardized low-fat diet
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Personalized diet
Number of subjects: 199
Study: 34395580

Group type: EXPERIMENTAL
Intervention: Autologous Protein Solution (APS)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Hyaluronic Acid plus Triamcinolone (HAT)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both APS and HAT
Number of subjects: 23
Study: 34767729

Group type: EXPERIMENTAL
Intervention: PP+ (Prevention Plus with caregiver goals)
Number of subjects: 73

Group type: COMPARATOR
Intervention: PP- (Prevention Plus without caregiver goals)
Number of subjects: 73
Study: 33047259

Group type: COMPARATOR
Intervention: RIPC
Number of subjects: 13

Group type: COMPARATOR
Intervention: RIPCaug
Number of subjects: 13

Group type: COMPARATOR
Intervention: CON
Number of subjects: 13
Study: 32741789

Group type: EXPERIMENTAL
Intervention: Mismatch (Mg) group using the Te.M.P.O. application
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (CTRLg) group using the Te.M.P.O. application
Number of subjects: 30